Bristol Myers Squibb (CELG-RI) Interest Coverage Ratio (2009 - 2026)
Bristol Myers Squibb (CELG-RI) posted quarterly Interest Coverage Ratio of 0.88 for Q2 2026, up 126.83% year-over-year from 0.39 in Q2 2025, and up 329.88% quarter-over-quarter from 0.38 in Q1 2026.
Bristol Myers Squibb (CELG-RI) Interest Coverage Ratio (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Interest Coverage Ratio for 18 consecutive years, with 0.88 the latest figure, recorded in Q2 2026.
- In Q2 2026, Interest Coverage Ratio rose 126.83% year-over-year to 0.88; the TTM figure through Jun 2026 stood at 1.57 (up 56.18% YoY), while the FY2025 annual figure was 1.79, up 84.37% from the prior year.
- Interest Coverage Ratio improved to 0.88 in Q2 2026 per CELG-RI's latest filing, from 0.38 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 0.88 in Q2 2026 and bottomed at 34.0 in Q1 2024.
- Historically, Interest Coverage Ratio has averaged 4.2 across 5 years, with a median of 2.44 in 2022.
- Annual changes were most pronounced in 2023 — Interest Coverage Ratio soared 130.28% — and 2024, when it slumped 5499.25%.
- Bristol Myers Squibb's Interest Coverage Ratio stood at 2.45 in 2022, then sank by 63.34% to 4.0 in 2023, then sank by 133.94% to 9.35 in 2024, then rose by 29.75% to 6.57 in 2025, then jumped by 113.47% to 0.88 in 2026.
- Business Quant data shows CELG-RI's Interest Coverage Ratio at 0.88 in Q2 2026, 0.38 in Q1 2026, and 6.57 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.51 Bn | 632.75 Bn | 17.26 Bn | 25.41 |
| 2 | AbbVie | 470.67 Bn | 464.10 Bn | 12.70 Bn | - |
| 3 | Merck | 378.00 Bn | 370.86 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.24 Bn | 295.55 Bn | 11.24 Bn | 10.28 |
| 5 | Astrazeneca | 257.85 Bn | 252.95 Bn | 12.86 Bn | 7.27 |
| 6 | Amgen | 236.64 Bn | 222.65 Bn | 7.24 Bn | 5.22 |
| 7 | Gilead Sciences | 182.27 Bn | 179.09 Bn | 6.22 Bn | -42.08 |
| 8 | Pfizer | 159.46 Bn | 147.76 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.20 Bn | 102.03 Bn | 8.24 Bn | -2.64 |
| 10 | Bristol Myers Squibb | 224.21 Mn | -10.84 Bn | 9.25 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.88 |
| Mar 31, 2026 | -0.38 |
| Dec 31, 2025 | -6.57 |
| Sep 30, 2025 | -0.67 |
| Jun 30, 2025 | -3.30 |
| Mar 31, 2025 | -0.10 |
| Dec 31, 2024 | -9.35 |
| Sep 30, 2024 | -2.54 |
| Jun 30, 2024 | -3.80 |
| Mar 31, 2024 | -34.00 |
| Dec 31, 2023 | -4.00 |
| Sep 30, 2023 | -1.32 |
| Jun 30, 2023 | -3.61 |
| Mar 31, 2023 | 0.63 |
| Dec 31, 2022 | -2.45 |
| Sep 30, 2022 | -0.48 |
| Jun 30, 2022 | -2.43 |
| Mar 31, 2022 | -2.08 |
| Dec 31, 2021 | -1.66 |
| Sep 30, 2021 | -0.41 |